Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

Ophthalmology

Volumn 119, Issue 7, 2012, Pages 1399-1411

  Chakravarthy, Usha ^a   Harding, Simon P ^b   Rogers, Chris A ^c   Downes, Susan M ^d   Lotery, Andrew J ^e   Wordsworth, Sarah ^f   Reeves, Barnaby C ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ADULT; AGED; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EXUDATIVE MACULAR DEGENERATION; FACTORIAL DESIGN; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RISK; SENSITIVITY ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC CATARACT; TREATMENT OUTCOME; UVEITIS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONTRAST SENSITIVITY; COST OF ILLNESS; DRUG COSTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; QUALITY OF LIFE; READING; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84863327423     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.04.015     Document Type: Article

References (26)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. J.F. Arevalo, J. Fromow-Guerra, J.G. Sanchez Pan-American Collaborative Retina Study Group Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up Retina 28 2008 1387 1394
4. J.S. Schouten, E.C. La Heij, C.A. Webers A systematic review on the effect of bevacizumab in exudative age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 247 2009 1 11
5. A. Tufail, P.J. Patel, C. Egan ABC Trial Investigators Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study [report online] BMJ 340 2010 c2459 http://www.bmj.com/ highwire/filestream/362622/field-highwire-article-pdf/0.pdf Accessed April 6, 2012
6. R.M. Rich, P.J. Rosenfeld, C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 2006 495 511
7. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
8. F.L. Ferris III, A. Kassoff, G.H. Bresnick, I. Bailey New visual acuity charts for clinical research Am J Ophthalmol 94 1982 91 96
9. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
10. R.F. Spaide, Y.L. Fisher Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 2006 275 278
11. S.S. Lynch, C.M. Cheng Bevacizumab for neovascular ocular diseases Ann Pharmacother 41 2007 614 625
12. EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
13. D.G. Pelli, J.G. Robson, A.J. Wilkins The design of a new letter chart for measuring contrast sensitivity Clin Vis Sci 2 1988 187 199
14. I.L. Bailey, J.E. Lovie New design principles for visual acuity letter charts Am J Optom Physiol Opt 53 1976 740 745
15. M.E. McClure, P.M. Hart, A.J. Jackson Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 84 2000 244 250
16. H. Brown, R. Prescott Applied Mixed Models in Medicine 2nd ed. 2006 John Wiley and Sons Chichester
17. National Institute for Clinical Excellence Guide to The Methods of Technology Appraisal 2004 NICE London http://www.nice.org.uk/niceMedia/pdf/TAP- Methods.pdf Accessed April 6, 2012
18. British National Formulary [database online] 2004 BMJ Publishing Group, LTD, RCPCH Publications Ltd and the Royal Pharmaceutical Society of Great Britain London http://bnf.org/bnf/index.htm Accessed April 6, 2012
19. L. Curtis Unit Costs of Health and Social Care 2011 2011 PSSRU Personal Social Services Research Unit, University of Kent 129 150 91 http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf Accessed February 1, 2012
20. Department of Health NSRC4 NHS Trusts and PCTs combined reference cost schedules 2010-11 [download link] Published November 2011 http://www.dh.gov.uk/ en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-131140 Accessed April 6, 2012
21. NHS Information Centre NHS Staff Earnings January-March 2011 Updated June 23, 2011 http://www.ic.nhs.uk/statistics-and-data-collections/workforce/nhs- staff-earnings/nhs-staff-earnings-january - march-2011 Accessed April 6, 2012
22. S.P. Davidovic, S.V. Nikolic, N.J. Curic Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy Eur J Ophthalmol 2012 Feb 16 [Epub ahead of print]
23. T. Sato, K. Wada, H. Arahori Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity Am J Ophthalmol 153 2012 327 333
24. NHS. National Institute for Health and Clinical Excellence Technology Appraisal TA155. Macular degeneration (age-related)- ranibizumab and pegaptanib: cost template [download link] Updated March 30, 2010 http://guidance.nice.org. uk/TA155/CostingTemplate/xls/English Accessed April 6, 2012
25. M.L. Subramanian, G. Abedi, S. Ness Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial Eye (Lond) 24 2010 1708 1715
26. L.H. Curtis, B.G. Hammill, K.A. Schulman, S.W. Cousins Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch Ophthalmol 128 2010 1273 1279